Fenoldopam for preventing and treating acute kidney injury
Información
- DOI:
- https://doi.org/10.1002/14651858.CD012905Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 24 diciembre 2017see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Protocol
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Riñón y trasplante
- Copyright:
-
- Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
-
Draft the protocol: CIE, GCB, EE, EH
-
Study selection: CIE, GCB
-
Extract data from studies: CIE, GCB
-
Enter data into RevMan: CIE, GCB
-
Carry out the analysis: CIE,GCB
-
Interpret the analysis: CIE, GCB, EE, EH
-
Draft the final review: CIE, GCB
-
Disagreement resolution: EH
-
Update the review: CIE, GCB
Sources of support
Internal sources
-
College of Medicine of the University of Lagos, Nigeria.
Provision of necessary infrastructure support during the preparation of this protocol.
-
All India Institute of Medical Sciences, Bhopal, India.
Provision of necessary infrastructure support during the preparation of this protocol.
External sources
-
No sources of support supplied
Declarations of interest
-
CIE: none known
-
GCB: Dr Girish C Bhatt has received Indian Council of Medical Research (ICMR) international fellowship (IF) as young scientist for the year 2017‐18 in division of Pediatric Nephrology at Montreal's Children Hospital, Canada.
-
EE: none known
-
EH: none known
Acknowledgements
We wish to thank the referees for their comments and feedback during the preparation of this protocol.
Version history
| Published | Title | Stage | Authors | Version |
| 2017 Dec 24 | Fenoldopam for preventing and treating acute kidney injury | Protocol | Christopher I Esezobor, Girish C Bhatt, Emmanuel E Effa, Elisabeth M Hodson | |
| RIFLE classification | AKIN classification | KDIGO classification | ||||||
| Class | GFR/serum creatinine | Urine output | Stage | Serum creatinine | Urine output | Stage | Serum creatinine | Urine output |
| Risk | ↑ SCr ≥ 1.5 OR ↓ GFR ≥ 25% | < 0.5 mL/kg/h for 6 h | 1 | ↑ SCr ≥ 26.5 μmol/L OR ↑SCr ≥ 150% to 200% from baseline | < 0.5 mL/kg/h for > 6 h | 1 | ↑SCr to ≥ 1.5 to 1.9 times baseline OR ≥ 26.5 mmol/L increase | ≤ 0.5 mL/kg/h for 6 to 12 h |
| Injury | ↑ SCr ≥2 OR ↓ GFR ≥50% | < 0.5 mL/kg/h for 12 h | 2 | ↑ SCr > 200% to 300% from baseline | < 0.5 mL/kg/h for > 6 h | 2 | ↑SCr to 2.0 to 2.9 times baseline | 0.5 mL/kg/h for ≥ 12 h |
| Failure | ↑ SCr ≥ 3 OR ↓ GFR ≥ 75% OR if baseline SCr ≥ 353.6 μmol/L ↑ SCr > 44.2 μmol/L | < 0.3 mL/kg/h for 24 h OR anuria for 12 h | 3 | ↑ SCr > 300% (> 3 fold) from baseline or if baseline SCr ≥ 353.6 μmol/L ↑SCr ≥ 44.2 μmol/L; also includes patients requiring RRT independent of stage | < 0.3 mL/kg/h for 24 h OR anuria for 12 h | 3 | ↑SCr to 3.0 times baseline OR ↑ SCr to ≥ 353.6 mmol/L OR Initiation of RRT OR In patients ≤ 18 years, ↓ eGFR to ≤ 35 mL/min/1.73 m2 | < 0.3 mL/kg/h for ≥ 24 OR anuria for ≥ 12 h |
| Loss | Complete loss of kidney function > 4 weeks | ‐‐ | ‐‐ | ‐‐ | ‐‐ | ‐‐ | ‐‐ | ‐‐ |
| ESKD | Complete loss of kidney function > 3 months | ‐‐ | ‐‐ | ‐‐ | ‐‐ | ‐‐ | ‐‐ | ‐‐ |
| ESKD ‐ end‐stage kidney disease; (e)GFR ‐ (estimated) glomerular filtration rate; SCr ‐ serum creatinine | ||||||||
